Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 2, 2022
Purpose: Regulation FD Disclosure to furnish investor presentations and Q3 2022 earnings supplemental materials to institutional investors and analysts.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to distribute attached exhibits containing the financial data rather than reporting the figures directly within the 8-K text.
Material Changes
No material financial changes are detailed in the text of this filing. The document states that the attached investor presentations (Exhibits 99.1 and 99.2) replace all prior investor presentations filed by the Company.
Guidance, Outlook, and Risks
- Management Commentary: The Company is providing updated corporate and earnings supplemental materials for Q3 2022.
- Forward-Looking Statements: The information provided may be amended or updated at any time through future filings.
- Legal Disclaimer: The information in Item 7.01 and the attached exhibits is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Presentation) and Exhibit 99.2 (Q3 2022 Earnings Supplemental Materials) for actual financial figures and operational updates.
- Verify the availability of these documents on the Company's website (www.aquestive.com), noting the Company reserves the right to discontinue availability.
- Confirm that no prior investor presentations should be relied upon as they have been superseded by the attached exhibits.